Frontiers in medicine · 2025
ISImatsuda as a potential predictor of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Jing, Wang Yueqiu, Zhou Xinghang, Wen Zaixin, Chen Yu, Sun Yiqiong, Su Shuaiying, Lin Weiwei, Shen Ruiting, Sun Xiaoyu, Li Hongru, Yu Xia, Zhang Mingchen
Аннотация
BACKGROUND: This study aimed to determine the most efficacious insulin resistance (IR) indices to predict metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes mellitus (T2DM).
METHODS: This cross-sectional study included 1,587 patients with T2DM. MASLD was defined by abdominal ultrasound findings. Liver fibrosis risk was assessed with FIB-4. All participants underwent a 100 g standard steamed bread meal test. We analyzed basal IR indices (HOMA-IR, QUICKI, IAI, Bennett ISI) and post-stimulation IR indices (ISImatsuda, ISI0,120) to explore their associations with MASLD and liver fibrosis.
RESULTS: Participants were categorized into four groups according to IR indices quartiles. Among post-stimulation IR indices, MASLD detection rates in ISImatsuda Q1-Q4 groups were 65.7, 54.2, 37.0, and 22.2%, respectively. Logistic regression analysis revealed significantly increased odds ratios (ORs) for MASLD in ISImatsuda Q1-Q3 groups compared to the Q4 group (OR = 3.63, 2.53, and 1.53, respectively; all p < 0.05). Similar results were observed across other IR indices (all p < 0.05). There were no statistically significant differences in the detection rates of liver fibrosis or the ORs among the quartile groups of the IR indices (all p > 0.05). ROC curve analysis showed that ISImatsuda had superior predictive power for MASLD in patients with T2DM (AUC = 0.701). Based on these findings, a risk prediction model for MASLD in the T2DM population was constructed using age, body mass index (BMI), alanine aminotransferase (ALT), triglycerides (TG), and 2-h postprandial C-peptide (2 h CP).
CONCLUSION: Among the IR indices, ISImatsuda demonstrated the strongest correlation and highest predictive value for MASLD in T2DM.
METHODS: This cross-sectional study included 1,587 patients with T2DM. MASLD was defined by abdominal ultrasound findings. Liver fibrosis risk was assessed with FIB-4. All participants underwent a 100 g standard steamed bread meal test. We analyzed basal IR indices (HOMA-IR, QUICKI, IAI, Bennett ISI) and post-stimulation IR indices (ISImatsuda, ISI0,120) to explore their associations with MASLD and liver fibrosis.
RESULTS: Participants were categorized into four groups according to IR indices quartiles. Among post-stimulation IR indices, MASLD detection rates in ISImatsuda Q1-Q4 groups were 65.7, 54.2, 37.0, and 22.2%, respectively. Logistic regression analysis revealed significantly increased odds ratios (ORs) for MASLD in ISImatsuda Q1-Q3 groups compared to the Q4 group (OR = 3.63, 2.53, and 1.53, respectively; all p < 0.05). Similar results were observed across other IR indices (all p < 0.05). There were no statistically significant differences in the detection rates of liver fibrosis or the ORs among the quartile groups of the IR indices (all p > 0.05). ROC curve analysis showed that ISImatsuda had superior predictive power for MASLD in patients with T2DM (AUC = 0.701). Based on these findings, a risk prediction model for MASLD in the T2DM population was constructed using age, body mass index (BMI), alanine aminotransferase (ALT), triglycerides (TG), and 2-h postprandial C-peptide (2 h CP).
CONCLUSION: Among the IR indices, ISImatsuda demonstrated the strongest correlation and highest predictive value for MASLD in T2DM.